Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 17Gastrointestinal Stromal Tumors 10Neoplasms 5Neoplasm Metastasis 4Multiple Myeloma 4Kidney Neoplasms 4Urologic Neoplasms 2Thyroid Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Osteosarcoma 2Meningioma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Kidney Diseases 2Gastrointestinal Neoplasms 2Carcinoma, Hepatocellular 2Carcinoma 2Adenoma, Islet Cell 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thymoma 1Stomach Neoplasms 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rectal Neoplasms 1Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

Sunitinib 2spartalizumab 1pembrolizumab 1palbociclib 1enzalutamide 1bicalutamide 1avelumab 1aldesleukin 1Specimen Handling 1Receptors, Androgen 1Leuprolide 1Interleukin-2 1Health Information Exchange 1Goserelin 1Flutamide 1Blood Specimen Collection 1Axitinib 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Kidney Diseases × Sunitinib × 1 year × Clear all
NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

AstraZeneca

Phase 3 Active not recruiting
60 enrolled 15 charts
Genitourinary

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT02684006 2025-07-30

JAVELIN Renal 101

Pfizer

Phase 3 Completed
886 enrolled 37 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡